Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia

European Journal of Heart Failure

Volumn 19, Issue 5, 2017, Pages 682-685

  Berg, David D ^a   Vaduganathan, Muthiah ^a   Nohria, Anju ^a   Davids, Matthew S ^b   Alyea, Edwin P ^b   Torre, Matthew ^a   Padera, Robert F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE MB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DECITABINE; DEXAMETHASONE; DOPAMINE; FUROSEMIDE; IPILIMUMAB; LACTIC ACID; METHYLPREDNISOLONE; TROPONIN T;

ABDOMINAL PAIN; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATRIOVENTRICULAR BLOCK; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; CD3+ T LYMPHOCYTE; CELL DEATH; CENTRAL VENOUS PRESSURE; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLITIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CRACKLE; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISEASE DURATION; DRUG MEGADOSE; DYSPNEA; ELECTROCARDIOGRAPHY; FOOT EDEMA; HEART CATHETERIZATION; HEART MUSCLE BIOPSY; HEART PACING; HEART RIGHT BUNDLE BRANCH BLOCK; HEMATOCRIT; HEMODYNAMIC PARAMETERS; HUMAN; HUMAN TISSUE; HYPOTENSION; LACTATE BLOOD LEVEL; LEUKOCYTE COUNT; LUNG EDEMA; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; MYOCARDITIS; MYOSITIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY ARTERY CATHETER; RECURRENT DISEASE; SIGMOIDOSCOPY; SODIUM BLOOD LEVEL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; BIOPSY; CARDIAC MUSCLE; CELLULAR IMMUNITY; DRUG EFFECT; FATALITY; IMMUNOLOGY; PATHOLOGY; T LYMPHOCYTE;

AGED; BIOPSY; ELECTROCARDIOGRAPHY; FATAL OUTCOME; HUMANS; IMMUNITY, CELLULAR; IPILIMUMAB; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MYOCARDITIS; MYOCARDIUM; T-LYMPHOCYTES;

EID: 85019040293     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.806     Document Type: Article

References (10)

1. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974–1982.
2. Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, Hornick JL, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ, Leukemia, Lymphoma Society Blood Cancer Research Partnership. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 2016;375:143–153.
3. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749–1755.
4. Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer 2015;3:4.
5. Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015;3:11.
6. Tadokoro T, Keshino E, Makiyama A, Sasaguri T, Ohshima K, Katano H, Mohri M. Acute Lymphocytic myocarditis with anti-PD-1 antibody nivolumab. Circ Heart Fail 2016;9:e003514.
7. Mehta A, Gupta A, Hannallah F, Koshy T, Reimold S. Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma. Melanoma Res 2016;26:319–320.
8. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015;16:522–530.
9. Besler C, Urban D, Watzka S, Lang D, Rommel KP, Kandolf R, Klingel K, Thiele H, Linke A, Schuler G, Adams V, Lurz P. Endomyocardial miR-133a levels correlate with myocardial inflammation, improved left ventricular function, and clinical outcome in patients with inflammatory cardiomyopathy. Eur J Heart Fail 2016;18:1442–1451.
10. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Zamorano JL, Aboyans V, Achenbach S, Agewall S, Badimon L, Baron-Esquivias G, Baumgartner H, Bax JJ, Bueno H, Carerj S, Dean V, Erol C, Fitzsimons D, Gaemperli O, Kirchhof P, Kolh P, Lancellotti P, Lip GY, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Roffi M, Torbicki A, Vaz Carneiro A, Windecker S, Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 2017;19:9–42.